Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Sep - Newspaper advertisement in respect to Special window opened for lodgment of transfer and dematerialization request(s).
Source: Bse
RPG Life Sciences Limited (RPGLIFE)
Small CapPharma stocks · Small cap · NSE
RPG Life Sciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +7.7% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
RPGLIFED candles · FIT view+39.0%Latest close ₹2797.30 on 2026-10-21
Bar
-1.0%
RSI
48
MACD hist
-15.07
52W pos
76%
2026-10-21O ₹2826.00H ₹2849.70L ₹2730.00C ₹2797.30Vol 7,223 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
RPGLIFENifty PharmaNifty 500
- RPGLIFE
- -6.7%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -0.2 pp
Chart stats
21 Oct 2026- From 52W high
- -10.6%
- 52W range position
- 76%
- ATR (14)
- 5.0%
- Volume vs 20D
- 0.19x
- Avg traded value
- ₹11.6 Cr
- 20D price channel
- ₹2,671.1 - ₹3,127.8
₹3,127.8
₹1,733 - ₹3,127.8
₹139.9
Latest completed session
20-session average
61.6% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE57
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent75
Revenue +16.0% · PAT +19.2% YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model+14.1%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence77
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 75/100Rev +16% YoY · PAT +19% YoY · margin expansion · +11% QoQ
Filed 28 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹196 Cr | +16.0% | +10.7% |
| EBITDA | ₹43 Cr | +22.9% | +30.3% |
| Operating margin | 22.0% | +100 bps | +300 bps |
| PAT | ₹31 Cr | +19.2% | +3.3% |
| PAT margin | 15.8% | +44 bps | -113 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 41.00
- P/B
- 7.91
- EV/EBITDA
- 27.18
- Market Cap
- 4790.00Cr
Profitability
- ROE
- 19.30%
- ROCE
- 25.70%
- ROA
- 15.13%
- Dividend Y
- 0.83%
Growth (CAGR)
- Revenue 5Y
- 33.00%
- EPS 5Y
- 33.00%
- Revenue 3Y
- 32.00%
- EPS 3Y
- 32.00%
Balance Sheet
- Debt/Equity
- 0.03
- Interest Coverage
- 155.00×
- Altman Z
- 8.89
- Book Value
- 366.00
Cash Flow
- FCF Yield
- 2.96%
- FCF Positive Y
- 2/5
- OCF
- 56.00 Cr
- EPS TTM
- 72.34
Shareholding
- Promoter Hold
- 72.95%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 83%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 196+10.7% vs prev
Net Profit
₹ CrLatest: 31.0+3.3% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 48.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~7.2% over last month) — short-term momentum positive.
- RSI(14) at 48 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 11% off 52W high · 61% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
80
RS percentile
Stage 2 UptrendEstablished S2
1M return
+1.3%
3M return
-6.7%
6M return
+39.1%
1Y return
+14.5%
RS 1D
-1
RS 20D
+2
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 13.6% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +5.8%.
50-DMA
price above
200-DMA
price above
S2 entered
09 Jul 2026
S2 age
72 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 129.78-0.70%
RS vs Nifty 500130
Valuation & peers
U-Score 57 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 57 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation4/30
Growth18/25
Quality13/20
Balance Sheet11/15
Cash Flow6/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
57
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
57/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 14.1%.
- Balance sheet contributes 11/15 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Cash flow is weaker at 6/10; verify the latest quarterly trend.
- Quality is weaker at 13/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
41.0
PB
7.9
EV/EBITDA
27.2
ROE
19.3%
ROCE
25.7%
FCF Yield
3.0%
Debt/Equity
0.0
MoS
+14.1%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
57
Previous: 57
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+14.1%
Previous: +12.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
58
58
58
58
58
58
58
56
56
55
57
57
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹771.83
-262.4% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹3,255.3
+14.1% MoS
PEG
1.26
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KPL
Small
Kwality Pharmaceuticals Limited
Healthcare Services
match 166
54
46.3
22.6%
+4%
FAIR VALUE
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 166
35
43.7
14.3%
-27%
WATCHLIST
UNICHEMLAB
Small
Unichem Laboratories Limited
Healthcare Services
match 165
66
30.6
3.2%
+74%
UNDERVALUED
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 164
33
320.0
1.5%
-846%
WATCHLIST
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 163
46
113.0
22.2%
-146%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
RPG Life Sciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
77Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 83rd percentile of the scored universe and 76th percentile within Pharma. Main check: results consistency is weak at 41/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
81 docs text-extracted · 10 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
83rd percentile
overall median 67 · Pharma: 76th pctile, median 70 · Small: 86th pctile, median 66
Evidence depth
Financial-only
81 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
41
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 73%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.2%.
- ▸Debt/equity is 0.03.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching RPG Life Sciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep - RPG Life Sciences to attend Anand Rathi G-200 Summit 2026 on September 22 in Mumbai.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 2 Sep - RPG Active Pharma acquires Raghava Life Sciences API business for up to ₹135 crore, adding 300 KL capacity.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug - Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (LODR) Regulations, 2015, the details of the Analyst/Institutional …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Jul - RPG Life Sciences launches Naprosyn ES in India with Archerchem; pan-India exclusive marketing and distribution.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.